MX2013003716A - Metodo para purificacion de factor h de complemento. - Google Patents
Metodo para purificacion de factor h de complemento.Info
- Publication number
- MX2013003716A MX2013003716A MX2013003716A MX2013003716A MX2013003716A MX 2013003716 A MX2013003716 A MX 2013003716A MX 2013003716 A MX2013003716 A MX 2013003716A MX 2013003716 A MX2013003716 A MX 2013003716A MX 2013003716 A MX2013003716 A MX 2013003716A
- Authority
- MX
- Mexico
- Prior art keywords
- complement factor
- factor
- purification
- blood
- caprylate
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/18—Ion-exchange chromatography
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Analytical Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
La presente invención se refiere a un método para la purificación del Factor H del complemento a partir de una fuente que contiene el Factor H del complemento tal como la sangre o el plasma de la sangre, en particular un precipitado del caprilato de una fuente que contiene el Factor 1-1, que es obtenido por ejemplo por la adición de los iones del caprilato a las fracciones de la sangre o el plasma, caracterizado porque comprende las etapas de: a) proporcionar una fuente que contiene un Factor H, en particular la reconstitución de un precipitado del caprilato para proporcionar una solución que contiene el Factor H del complemento; b) efectuar una cromatografía de intercambio catiónico, en particular como una primera etapa cromatográfica; c) efectuar una cromatografía de intercambio aniónico; d) efectuar la cromatografía sobre la hidroxilo-apatita; e) seguido por la ultra/diafiltración para obtener un concentrado del Factor H del complemento.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US34480510P | 2010-10-13 | 2010-10-13 | |
| EP10187410 | 2010-10-13 | ||
| PCT/EP2011/067883 WO2012049245A1 (en) | 2010-10-13 | 2011-10-13 | Method for purification of complement factor h |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2013003716A true MX2013003716A (es) | 2013-05-09 |
Family
ID=43332833
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2013003716A MX2013003716A (es) | 2010-10-13 | 2011-10-13 | Metodo para purificacion de factor h de complemento. |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US8809510B2 (es) |
| EP (1) | EP2627348A1 (es) |
| KR (1) | KR20130128382A (es) |
| CN (1) | CN103153333B (es) |
| AU (1) | AU2011315466B2 (es) |
| BR (1) | BR112013009065A2 (es) |
| CA (1) | CA2812643A1 (es) |
| MX (1) | MX2013003716A (es) |
| RU (1) | RU2013121589A (es) |
| WO (1) | WO2012049245A1 (es) |
| ZA (1) | ZA201302573B (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2988298A1 (fr) * | 2012-03-23 | 2013-09-27 | Lfb Biotechnologies | Facteur h pour son utilisation comme molecule antioxydante |
| AU2013203043B2 (en) | 2013-03-15 | 2016-10-06 | Takeda Pharmaceutical Company Limited | Methods to produce a human plasma-derived igg preparation enriched in brain disease-related natural iggs |
| KR101592309B1 (ko) * | 2013-11-21 | 2016-02-05 | 주식회사 녹십자 | 대체경로 억제제를 함유하는 신장 질환 예방 또는 치료용 조성물 및 이를 이용한 신장 질환 예방 또는 치료방법 |
| US10155983B2 (en) | 2014-03-31 | 2018-12-18 | Machaon Diagnostics, Inc. | Method of diagnosis of complement-mediated thrombotic microangiopathies |
| CN113045634B (zh) * | 2019-12-28 | 2023-04-28 | 四川远大蜀阳药业有限责任公司 | 一种补体h因子制备方法 |
| CN114605519B (zh) * | 2020-12-03 | 2023-10-31 | 四川远大蜀阳药业有限责任公司 | 提取h因子的方法 |
| KR20230148961A (ko) * | 2022-04-19 | 2023-10-26 | 에스케이플라즈마 주식회사 | 면역글로불린 정제방법 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5886154A (en) | 1997-06-20 | 1999-03-23 | Lebing; Wytold R. | Chromatographic method for high yield purification and viral inactivation of antibodies |
| PT1718675E (pt) * | 2004-02-27 | 2013-05-21 | Octapharma Ag | Método de proporcionar uma preparação purificada de anticorpos livre de vírus |
| CA2627264A1 (en) * | 2005-09-19 | 2007-04-12 | Csl Behring Gmbh | Factor h for the treatment of chronic nephropathies and production thereof |
| FR2894145B1 (fr) | 2005-12-07 | 2008-10-17 | Lab Francais Du Fractionnement | Utilisation de facteur h du complement a titre de medicament |
| ES2595059T3 (es) * | 2007-03-20 | 2016-12-27 | Csl Behring Gmbh | Métodos para la producción a escala industrial de preparados terapéuticos del Factor H del complemento a partir de plasma humano |
-
2011
- 2011-10-13 EP EP11770100.3A patent/EP2627348A1/en not_active Withdrawn
- 2011-10-13 AU AU2011315466A patent/AU2011315466B2/en not_active Ceased
- 2011-10-13 MX MX2013003716A patent/MX2013003716A/es not_active Application Discontinuation
- 2011-10-13 US US13/879,283 patent/US8809510B2/en not_active Expired - Fee Related
- 2011-10-13 WO PCT/EP2011/067883 patent/WO2012049245A1/en not_active Ceased
- 2011-10-13 CA CA2812643A patent/CA2812643A1/en not_active Abandoned
- 2011-10-13 RU RU2013121589/15A patent/RU2013121589A/ru not_active Application Discontinuation
- 2011-10-13 KR KR1020137009110A patent/KR20130128382A/ko not_active Withdrawn
- 2011-10-13 BR BR112013009065A patent/BR112013009065A2/pt not_active IP Right Cessation
- 2011-10-13 CN CN201180049586.5A patent/CN103153333B/zh not_active Expired - Fee Related
-
2013
- 2013-04-10 ZA ZA2013/02573A patent/ZA201302573B/en unknown
-
2014
- 2014-07-09 US US14/327,110 patent/US20150031621A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CN103153333B (zh) | 2015-09-09 |
| RU2013121589A (ru) | 2014-11-20 |
| US8809510B2 (en) | 2014-08-19 |
| KR20130128382A (ko) | 2013-11-26 |
| ZA201302573B (en) | 2013-12-23 |
| CA2812643A1 (en) | 2012-04-19 |
| AU2011315466B2 (en) | 2015-10-29 |
| BR112013009065A2 (pt) | 2016-07-19 |
| EP2627348A1 (en) | 2013-08-21 |
| WO2012049245A1 (en) | 2012-04-19 |
| CN103153333A (zh) | 2013-06-12 |
| US20130203971A1 (en) | 2013-08-08 |
| AU2011315466A1 (en) | 2013-04-04 |
| US20150031621A1 (en) | 2015-01-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2013003716A (es) | Metodo para purificacion de factor h de complemento. | |
| GEP20207056B (en) | New bicyclic derivatives, a process for their preparation and pharmaceutical compositions containing them | |
| WO2016100261A3 (en) | Method of treating cancer with cgamp or cgasmp | |
| PH12013502565A1 (en) | Substituted imidazopyridinyl-aminopyridine compounds | |
| AU2012313399A8 (en) | 8-ethyl-6-(aryl)pyrido [2,3-d]pyrimidin-7(8H) -ones for the treatment of nervous system disorders and cancer | |
| JO3092B1 (ar) | مركب لتحفيز مسيطر عليه للمبيض | |
| MX342920B (es) | Metodo para purificar polipeptidos o inmunoconjugados activos. | |
| EA201790876A1 (ru) | Способ контроля, предотвращения или лечения кровотечения | |
| EA201590442A1 (ru) | Способ получения изотопа | |
| AU2012213775A8 (en) | 7-azaindole derivatives | |
| WO2013187971A3 (en) | Macrocycles | |
| MX2013000958A (es) | Fabricación del inhibidor-inter-alfa (iaip) a partir de plasma. | |
| WO2012013682A3 (en) | Protein purification | |
| GEP201706690B (en) | Novel process for making compounds for use in treatment of cancer | |
| PH12013501688A1 (en) | Treatment of amyotrophic lateral sclerosis using umbilical derived cells | |
| MD20160018A2 (ro) | Noi compuşi de izoindolină sau izochinolină, procedeu de obţinere a lor şi compoziţii farmaceutice care îi conţin | |
| MX347882B (es) | Procedimiento mejorado para preparar (3e, 7e)-homofarnesol. | |
| HK1204303A1 (en) | Process for preparing a c3-c7 (hydro) fluoroalkene by dehydrohalogenation | |
| WO2012104823A3 (en) | Pyridopyrimidinone compounds in the treatment of neurodegenerative diseases | |
| PH12014501909B1 (en) | Method for preparing human immunoglobulin | |
| HK1209105A1 (en) | Vegfr3 inhibitors | |
| NZ700356A (en) | Pyrazole compounds as sglt1 inhibitors | |
| EA201400273A1 (ru) | Способ снижения тромбоэмболического потенциала композиции, содержащей полученный из плазмы иммуноглобулин | |
| WO2014086453A8 (en) | Azaheterobicyclic compounds | |
| MX368474B (es) | Uso de benralizumab para mejorar síntomas de asma. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |